⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544669 | 0.74 | — | — | |
| SCHEMBL31283823 | 0.74 | — | — | |
| SCHEMBL9572667 | 0.74 | — | — | |
| SCHEMBL559207 | 0.74 | — | — | |
| SCHEMBL7318342 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL8785894 | 0.72 | — | — | |
| SCHEMBL3025298 | 0.72 | — | — | |
| SCHEMBL7320440 | 0.70 | — | — | |
| SCHEMBL9686638 | 0.70 | — | — | |
| SCHEMBL3025299 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-2712315-B1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | ORYZON GENOMICS SA (ES) | 2021-11-24 | — | — | EP | disclosed |
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3686182-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20200207782-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2020-07-02 | — | — | US | disclosed |
| US-10683274-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040132726-A1 | heterocyclic compounds, e.g., 4-(5-m-Tolyl-[1,2,4]oxadiazol-3-ylmethyl)-piperazine-1-carboxylic acid ethyl ester; treatment of mGluR5 receptor-mediated disorders, particularly neurological disorders, psychiatric disorders, acute and chronic pain. | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004014370-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0177965-B1 | NOVEL OXA- AND THIADIAZOLYL DERIVATIVES AND THEIR USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-03-21 | — | — | EP | disclosed |
| US-4705786-A | Novel oxadiazolyl-1,4-dihydropyridines useful as antihypertensive agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-10 | — | — | US | disclosed |
| EP-0177965-A2 | Novel oxa- and thiadiazolyl derivatives and their use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |